RVU-120 is under clinical development by Ryvu Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RVU-120’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RVU-120 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RVU-120 is under development for the treatment of hematological tumors, acute lymphoblastic leukemia, triple negative breast cancer, myeloproliferative disorders, lymphomas including mantle cell lymphoma, non-Hodgkin lymphoma, solid tumors including colorectal cancer, breast cancer, prostate cancer, Wilms tumor and rare anemia including Diamond Blackfan anemia (congenital hypoplastic anemia), relapsed/refractory acute myeloid leukemia, diffuse large B-cell lymphoma and myelodysplastic syndrome. The drug candidate is administered through oral route. It acts by targeting Cyclin Dependent Kinase 19 and Cyclin Dependent Kinase 8.
Ryvu Therapeutics overview
Ryvu Therapeutics is a biopharmaceutical company that specializes in novel small molecule therapies addressing high-value emerging targets in precision oncology. Ryvu Therapeutics is headquartered in Krakow, Poland.
Quick View RVU-120 LOA Data
|Highest Development Stage|